New imaging technique could reveal how cancer drugs target tumors

NCT ID NCT07440212

Not yet recruiting Diagnosis Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test a new type of PET scan that uses a radioactive tag to track an experimental antibody (ivonescimab) in people with esophageal cancer. The goal is to see where the antibody goes in the body and how well it targets tumors, which could help doctors choose the right treatments. About 50 adults with esophageal cancer will receive the tagged antibody and then have PET scans to measure its distribution. The study does not treat the cancer but aims to improve how we monitor and predict treatment response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGUS CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGUS CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Daping Hospital, Army Medical University

Chongqing, Chongqing Municipality, 400010, China